文献速递系统性红斑狼疮类风湿关节炎其他结缔组织病

G6PDH 缺乏患者使用羟氯喹与溶血性贫血的考察

Examination of Hydroxychloroquine Use and Hemolytic Anemia in G6PDH-Deficient Patients.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2018-02-09

本研究通过回顾性病历审查,评估 Duke 大学医学中心风湿科使用羟氯喹(HCQ)且检测过 G6PDH 水平的患者中,G6PDH 缺乏者因 HCQ 发生溶血的情况。275 例患者中仅 4% 为 G6PDH 缺乏(均为非裔美国人),11 例 G6PDH 缺乏者在超过 700 个月的 HCQ 暴露期间未报告溶血发作,2 例溶血发生于未使用 HCQ 的重度狼疮 flare 期间。数据不支持对非裔美国人 G6PDH 缺乏者常规检测 G6PDH 或停用 HCQ。

要点

  • 11 例 G6PDH 缺乏者超过 700 个月 HCQ 暴露期间无溶血报告。
  • 2 例溶血发生在未用 HCQ 的重度狼疮 flare 期间。
  • 不支持下述做法:对非裔美国人 G6PDH 缺乏者常规测 G6PDH 或停用 HCQ。

核心结论

  • G6PDH 缺乏患者中因 HCQ 发生溶血的情况未见报告,数据不支持常规检测 G6PDH 或停用 HCQ。

研究设计与样本

  • 回顾性病历审查,纳入 Duke 大学医学中心风湿科使用 HCQ 且检测过 G6PDH 水平的患者,共 275 例。

主要发现

  • 275 例中 84% 为女性,46% 为非裔美国人,48% 为白人。
  • 主要诊断依次为系统性红斑狼疮 32%、类风湿关节炎 29%、炎症性关节炎 14%。
  • 仅 4% 患者 G6PDH 缺乏,且均为非裔美国人。
  • 11 例 G6PDH 缺乏者超过 700 个月 HCQ 暴露期间无溶血报告,2 例溶血发生于未用 HCQ 的重度狼疮 flare 期间。

临床怎么用

  • 对非裔美国人 G6PDH 缺乏患者,不必常规检测 G6PDH 水平,也不必因此停用 HCQ。

局限性

  • 为单中心回顾性病历审查,G6PDH 缺乏者仅 11 例,样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Some sources urge caution when prescribing hydroxychloroquine (HCQ) to patients with G6PDH deficiency, presumably due to a risk of hemolytic anemia. There are limited published data, however, to support this risk. Additionally, not all patients with G6PDH deficiency are at similar risk for hemolysis, and people with the African variant are at particularly low risk. Through a retrospective chart review, we aimed to quantify the frequency of G6PDH-deficient patients with hemolysis attributed to HCQ. METHODS: We identified Duke University Medical Center rheumatology patients with HCQ use and a measured G6PDH level. A retrospective chart review was performed, recording demographics, G6PDH levels, episodes of anemia, laboratory values consistent with hemolysis, and HCQ use. RESULTS: Of the 275 patients reviewed, 84% were female; 46% were African American and 48% were white. The leading diagnoses were systemic lupus erythematosus (32%), rheumatoid arthritis (29%), and inflammatory arthritis (14%). Only 4% of patients were G6PDH deficient (all African American). Two G6PDH-deficient patients had hemolysis during severe lupus flares that occurred while not taking HCQ. There were no reported episodes of hemolysis in more than 700 months of HCQ exposure among the 11 G6PDH-deficient patients. CONCLUSION: This is the largest study to date evaluating G6PDH deficiency with concurrent use of HCQ. Of 11 patients with G6PDH deficiency, 2 had episodes of hemolysis, but these did not occur during HCQ therapy. These data do not support routine measurement of G6PDH levels or withholding HCQ therapy among African American patients with G6PDH deficiency.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Mohammad S, Clowse MEB, Eudy AM, et al. Examination of Hydroxychloroquine Use and Hemolytic Anemia in G6PDH-Deficient Patients. Arthritis Care Res (Hoboken). 2018. PMID: 28556555. doi:10.1002/acr.23296

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。